QIAGEN reported robust operational performance in 2025, meeting key growth and profitability targets across its five strategic pillars. The company enters 2026 with a clear roadmap to reach $2 billion in combined annual pillar sales by 2028. Investments this year will focus on automation systems, menu expansions and AI-driven bioinformatics, supplemented by targeted acquisitions to accelerate market share gains in life sciences and molecular diagnostics. QIAGEN’s QIAstat-Dx installed base exceeded 5,200 instruments at year-end 2025, underpinning the December submission of blood culture identification panels in the U.S. and Europe. The menu now covers six U.S.-cleared and three CE-registered panels, with additional assays for complicated urinary tract infections and pneumonia in development. On the digital PCR front, cumulative QIAcuity placements surpassed 3,200 by year-end, and QIAGEN will introduce thousands of new gene expression assays in 2026. Collaboration with Hamilton on an automated nanoplate handling solution will enable walkaway workflows in GMP-regulated environments. QIAGEN Digital Insights (QDI) plans to launch 14 AI-enabled software solutions by 2028, starting with new capabilities for pharmaceutical R&D, multilingual clinical reporting and AI decision support for target identification. Integration of the Genoox-acquired Franklin platform will accelerate genetic analysis workflows. In tuberculosis diagnostics, QIAGEN is developing a fifth-generation QuantiFERON test and new chemistry for Diasorin’s LIAISON platform, which boosts throughput by up to 75% and speeds results by 25%. With one in four people globally carrying latent TB, QIAGEN is investigating AI tools to guide preventive treatment and convert share from traditional skin tests. In December 2025, QIAGEN completed its acquisition of Parse Biosciences, adding single-cell analysis to its Sample technologies portfolio. Parse’s Evercode chemistry, used by more than 3,000 customers, is expected to contribute approximately $40 million in revenue in 2026. QIAGEN will leverage its global commercial network to scale Parse’s offerings and plans to launch three new automated sample preparation systems—QIAsymphony Connect, QIAsprint Connect and QIAmini—during 2026 to address demand in liquid biopsy, microbiome research and minimal residual disease testing.